Last reviewed · How we verify
Sulfadoxine pyrimethamine + Amodiaquin
Sulfadoxine pyrimethamine + Amodiaquin is a Antimalarial Small molecule drug developed by University Clinical Research Center, Mali. It is currently in Phase 3 development for Malaria treatment and prevention. Also known as: SPAQ.
Sulfadoxine pyrimethamine is a combination of a sulfonamide antibiotic and a dihydrofolate reductase inhibitor, while amodiaquine is a 4-aminoquinoline antimalarial.
Sulfadoxine pyrimethamine is a combination of a sulfonamide antibiotic and a dihydrofolate reductase inhibitor, while amodiaquine is a 4-aminoquinoline antimalarial. Used for Malaria treatment and prevention.
At a glance
| Generic name | Sulfadoxine pyrimethamine + Amodiaquin |
|---|---|
| Also known as | SPAQ |
| Sponsor | University Clinical Research Center, Mali |
| Drug class | Antimalarial |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Sulfadoxine pyrimethamine works by inhibiting the growth of the malaria parasite, while amodiaquine targets the parasite's DNA replication. This combination therapy is effective against chloroquine-resistant strains of malaria.
Approved indications
- Malaria treatment and prevention
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Rash
- Allergic reactions
Key clinical trials
- Perennial Malaria Chemoprevention in the Malaria Vaccine Era (PHASE4)
- Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi (PHASE4)
- Parasite Clearance and Protection from Infection (PCPI) in Cameroon (PHASE3)
- Efficacy and Safety of Sulphadoxine-pyrimethamine and Amodiaquine in Ghanaian Pregnant Women (PHASE3)
- Evaluation of Vector and Chemoprevention-based Interventions to Reduce Malaria Burden in Urban Daaras of Touba, Senegal (PHASE4)
- Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ) Extension Study (PHASE3)
- Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE) (PHASE4)
- Seasonal Malaria Chemoprevention Rapid Assessment Study Mozambique (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sulfadoxine pyrimethamine + Amodiaquin CI brief — competitive landscape report
- Sulfadoxine pyrimethamine + Amodiaquin updates RSS · CI watch RSS
- University Clinical Research Center, Mali portfolio CI
Frequently asked questions about Sulfadoxine pyrimethamine + Amodiaquin
What is Sulfadoxine pyrimethamine + Amodiaquin?
How does Sulfadoxine pyrimethamine + Amodiaquin work?
What is Sulfadoxine pyrimethamine + Amodiaquin used for?
Who makes Sulfadoxine pyrimethamine + Amodiaquin?
Is Sulfadoxine pyrimethamine + Amodiaquin also known as anything else?
What drug class is Sulfadoxine pyrimethamine + Amodiaquin in?
What development phase is Sulfadoxine pyrimethamine + Amodiaquin in?
What are the side effects of Sulfadoxine pyrimethamine + Amodiaquin?
Related
- Drug class: All Antimalarial drugs
- Manufacturer: University Clinical Research Center, Mali — full pipeline
- Therapeutic area: All drugs in Infectious Diseases
- Indication: Drugs for Malaria treatment and prevention
- Also known as: SPAQ
- Compare: Sulfadoxine pyrimethamine + Amodiaquin vs similar drugs
- Pricing: Sulfadoxine pyrimethamine + Amodiaquin cost, discount & access